Quest Stock Hits New 52-Week High (DGX)

NEW YORK ( TheStreet) -- Quest Diagnostics (NYSE: DGX) hit a new 52-week high Thursday as it is currently trading at $62.39, above its previous 52-week high of $62.32 with 1.1 million shares traded as of 11:05 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.

Quest has a market cap of $9.62 billion and is part of the health care sector and health services industry. Shares are up 4.5% year to date as of the close of trading on Wednesday.

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company has a P/E ratio of 14.3, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Quest as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, expanding profit margins, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated. You can view the full Quest Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Cramer: These Sectors Look Bullish (Part III)

Cramer: There Are Powerful Themes in Several Bull Markets

Stanley Black & Decker, Quest Diagnostics and 2 More Could Rocket Higher This Spring -- Here's Why

MasterCard, Intuitive Surgical and 2 More Could Rocket Higher This Spring--Here's Why …

Market Recon: If You Are Scared, Don't Show It